Emisphere Technologies competitorsClear all

Emisphere Technologies's top competitors include Reata Pharmaceuticals, Otonomy, MyoKardia and Biogen.
Emisphere Technologies
Emisphere Technologies
Emisphere Technologies is a commercial-stage pharmaceutical and drug delivery company.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Founding Date
Founding Date
1986
Founding Date
2002
Founding Date
2008
Founding Date
2012
Founding Date
1978
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Roseland, US HQ
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
San Diego, US HQ
Locations
South San Francisco, US HQ
Brisbane, US
Locations
Cambridge, US HQ
Vicente López, AR
North Ryde, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Employees
Employees
650% decrease
Employees
22079% increase
Employees
49
Employees
23542% increase
Employees
7,4005% decrease
Valuation ($)
Valuation ($)
677.1 m
Valuation ($)
3.6 b
Valuation ($)
164.5 m
Valuation ($)
6.9 b
Valuation ($)
43.1 b
Twitter followers
Twitter followers
448
Twitter followers
952
Twitter followers
226
Twitter followers
1 k
Twitter followers
33.9 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
57
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
4.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
20.7
Average likes per tweet (last 30 days)
35.8
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
93.33%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
317476
Alexa Website Rank
365810
Alexa Website Rank
339305
Alexa Website Rank
239431
Alexa Website Rank
254464
Employee Rating
Employee Rating
2
Employee Rating
4
Employee Rating
4.3
Employee Rating
4.2
Employee Rating
3.8

Financial

Revenue (est.)
Revenue (est.)
$1.2m (FY, 2016)
Revenue (est.)
$26.5m (FY, 2019)
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$14.4b (FY, 2019)
Cost of goods
Cost of goods
$286k (FY, 2016)
Cost of goods
N/A
Cost of goods
$912k (FY, 2019)
Cost of goods
N/A
Cost of goods
$2b (FY, 2019)
Gross profit
Gross profit
$909k (FY, 2016)
Gross profit
N/A
Gross profit
($312k) (FY, 2019)
Gross profit
N/A
Gross profit
$12.4b (FY, 2019)
Net income
Net income
($10m) (FY, 2016)
Net income
($290.2m) (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
$5.9b (FY, 2019)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
2 (FY, 2018)
Patents (US)
21 (FY, 2019)
Patents Issued
Patents Issued
N/A
Patents Issued
240 (FY, 2016)
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Pending
Patents Pending
N/A
Patents Pending
280 (FY, 2016)
Patents Pending
115 (FY, 2016)
Patents Pending
N/A
Patents Pending
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
11 (Q2, 2020)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
10 (Q2, 2020)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
6 (Q2, 2020)
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
3 (FY, 2018)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 468.9m
Total funding raised
$ 153.4m
Total funding raised
$ 98m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Reata Pharmaceuticals
HQ
Plano, US
Employees
220

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company